Overview

Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors

Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 in subjects with advanced or metastatic solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
I-Mab Biopharma Co. Ltd.